Mark H Zoller from 33 Harborhead Dr, Point Pleasant Beach, NJ 08742, age 67

Name / Title

Company / Classification

Phones & Addresses

Mark Zoller
Controller

National Labnet Co
Professional Equipment and Supplies

31 Mayfield Ave, Edison, NJ 08837

Mark Zoller
Finance Executive

National Labnet Co
Professional Equipment and Supplies

31 Mayfield Ave, Edison, NJ 08837

Mark Zoller
Finance Executive, Controller

National Labnet Co
Whol Professional Equip Mfg Lab Apparatus/Furn Mfg Analytical Instr

31 Mayfield Ave, Edison, NJ 08837
PO Box 841, Woodbridge, NJ 07095
732 417-0700

Mark Zoller
Controller

Labnet International Inc
Mfg Industrial Organic Chemicals · Mfg Lab Apparatus/Furniture

31 Mayfield Ave, Edison, NJ 08837

Medicine Doctors

Mark A. Zoller

view source

Specialties:

Family Medicine

Work:

Saint Vincents Primary Care
3690 Saint Johns Blf Rd S, Jacksonville, FL 32224
904 645-6767 (phone), 904 645-0145 (fax)

Education:

Medical School
University of Kentucky College of Medicine
Graduated: 1984

Procedures:

Arthrocentesis
Cardiac Stress Test
Destruction of Benign/Premalignant Skin Lesions
Electrocardiogram (EKG or ECG)
Osteopathic Manipulative Treatment
Pulmonary Function Tests
Skin Tags Removal
Vaccine Administration

Conditions:

Abnormal Vaginal Bleeding
Acne
Acute Pharyngitis
Alcohol Dependence
Alopecia Areata

Languages:

English

Description:

Dr. Zoller graduated from the University of Kentucky College of Medicine in 1984. He works in Jacksonville, FL and specializes in Family Medicine. Dr. Zoller is affiliated with St Vincents Medical Center and St Vincents Medical Center Southside.

License Records

Mark Zoller

License #:

AAC-0856 - Active

Category:

Asbestos Program

Issued Date:

Jan 24, 2011

Type:

Consultant BASE

Resumes

Mark Zoller

view source

Mark Zoller

view source

Mark Zoller

view source

Mark Zoller

view source

Mark Zoller

view source

Mark Zoller

view source

Location:

United States

Isbn (Books And Publications)

Recombinant Dna
view source
Author:

Mark Zoller
ISBN #:

0716722828

Us Patents

Tussue Plasminogen Activator Having Zymogenic Or Fibrin Specific Properties
view source
US Patent:

58405640, Nov 24, 1998
Filed:

Sep 9, 1997
Appl. No.:

8/926362
Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Bottstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C07H 2104
C12N 964
US Classification:

435226
Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

Tissue Plasminogen Activator Having Zymogenic Or Fibrin Specific Properties
view source
US Patent:

57285675, Mar 17, 1998
Filed:

Aug 1, 1996
Appl. No.:

8/662891
Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C12N 964
C12N 1558
C12N 1570
C12N 1586
US Classification:

435226
Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

Tissue Plasminogen Activator Having Zymogenic Properties
view source
US Patent:

55209130, May 28, 1996
Filed:

Jul 6, 1993
Appl. No.:

8/088451
Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA
Assignee:

Genentech, Inc. - San Francisco CA
International Classification:

C12N 950
C12N 964
A61K 3849
C07H 1512
US Classification:

424 9464
Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

Tissue Plasminogen Activator Having Zymogenic Or Fibrin Specific Properties
view source
US Patent:

56141904, Mar 25, 1997
Filed:

Apr 26, 1995
Appl. No.:

8/429364
Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA
Assignee:

Genentech, Inc. - So. San Francisco CA
International Classification:

A61K 3849
C12N 950
C12N 964
C12N 1555
US Classification:

424 9464
Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

Tissue Plasminogen Activator Having Zymognic Or Fibrin Specific Properties
view source
US Patent:

58211055, Oct 13, 1998
Filed:

Oct 17, 1996
Appl. No.:

8/733124
Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C12N 964
US Classification:

435226
Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

Tissue Plasminogen Activator Having Zymogenic Or Fibrin Specific Properties And Substituted At Amino Acid Positions 296-299, Dna Molecules Encoding Them, Vectors, And Host Cells
view source
US Patent:

52621707, Nov 16, 1993
Filed:

Oct 3, 1991
Appl. No.:

7/770510
Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C12N 964
C12N 1558
A61K 37547
US Classification:

424 9464
Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

Tissue Plasminogen Activator Having Zymogenic Or Fibrin Specific Properties
view source
US Patent:

51089017, Apr 28, 1992
Filed:

Jul 24, 1989
Appl. No.:

7/384608
Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Carlos CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

C12N 950
C12N 964
C12Q 138
C07H 1512
US Classification:

435 23
Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

Tissue Plasminogen Activator Having Zymogenic Or Fibrin Specific Properties
view source
US Patent:

57704260, Jun 23, 1998
Filed:

Jun 12, 1996
Appl. No.:

8/660986
Inventors:

Stephen Anderson - Princeton NJ
William F. Bennett - San Mateo CA
David Botstein - Belmont CA
Deborah L. Higgins - San Mateo CA
Nicholas F. Paoni - Moraga CA
Mark J. Zoller - San Francisco CA
Assignee:

Genentech, Inc. - South San Francisco CA
International Classification:

A61K 3848
C12N 964
C12N 1563
US Classification:

435226
Abstract:

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.